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Background: Oncologic patients who are extreme responders to molecularly targeted therapy provide an
important opportunity to better understand the biologic basis of response and, in turn, inform clinical decision
making. Malignant neoplasms with an uncertain histologic and immunohistochemical characterization present
challenges both on initial diagnostic workups and then later in management, as current treatment algorithms are
based on a morphologic diagnosis. Herein, we report a case of a difficult to characterize sarcoma-like lesion for
which genomic profiling with clinical next generation sequencing (NGS) identified the molecular underpinnings of
arrested progression(stable disease) under combination targeted therapy within a phase I clinical trial.
Methods: Genomic profiling with clinical next generation sequencing was performed on the FoundationOne™
platform (Foundation Medicine, Cambridge MA). Histopathology and immunohistochemical studies were performed
in the Department of Pathology, MD Anderson Cancer Center (Houston, TX). Treatment was administered in the
context of a phase I clinical trial ClinicalTrials.gov Identifier: (NCT01187199).
Results: The histology of the tumor was that of a spindle cell neoplasm, grade 2 by FNCLCC standards.
Immunohistochemical staining was positive for S100 and CD34. Genomic profiling identified the following
alterations: a KIAA1549-BRAF gene fusion resulting from a tandem duplication event, a homozygous deletion of
PTEN, and frameshift insertion/deletions in CDKN2A A68fs*51, SUFU E283fs*3, and MAP3K1 N325fs*3. The patient had
a 25% reduction in tumor (RECIST v1.1) following combination therapy consisting of sorafenib, temsirolimus, and
bevazicumab within a phase I clinical trial.
Conclusions: The patient responded to combination targeted therapy that fortuitously targeted KIAA1549-BRAF and
PTEN loss within a spindle cell neoplasm, as revealed by genomic profiling based on NGS. This is the first report of
a tumor driven by a KIAA1549-BRAF fusion responding to sorafenib-based combination therapy.
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Tumors that defy ready histopathologic characterization
are difficult to rationally approach in the setting of treat-
ment algorithms which are based on the anatomic origin
of the neoplasm. Spindle cell neoplasms are such tumors
that defy characterization even with ancillary methods
such as immunohistochemistry. In such cases, genomic
profiling based on next generation sequencing (NGS) can
identify the genomic alterations (GA) that drive oncogen-
esis and thus prospectively suggest aberrantly activated
pathways for pharmacologic inhibition independent of
tumor site origin. Conversely, in the case of exceptional
responders to targeted therapy, diagnostic genomic pro-
filing may uncover the linked underlying alterations
retrospectively. We report one such case of a patient
with a malignant spindle cell neoplasm who exhibited
clinical and radiographic improvement with simultaneous
RAF kinase inhibition (sorafenib/Nexavar®), mTOR inhib-
ition (temsirolimus/Torisel®) and VEGF (bevacizumab/
Avastin®) targeted therapy who had been refractory to
standard cyototoxic chemotherapy. A Clinical Laboratory
Improvement Amendments (CLIA) laboratory performed
NGS-based diagnostic genomic profiling which identified
this tumor as the first reported case of the KIAA1549-
BRAF fusion in a PTEN null background as a driving gen-
omic alteration susceptible to targeted therapy.Patients and methods
Patient selection and clinical assessments
We reviewed the medical records of a patient with spindle
cell neoplasm who presented to the Department of Inves-
tigational Cancer Therapeutics at The University of Texas
MD Anderson Cancer Center after failing standard of care
therapy. Treatment and consent on investigational trial,
and data collection were performed in accordance with
the guidelines of the University of Texas MD Anderson
Cancer Center Institutional Review Board (IRB). Tumor
response was determined using RECIST (version 1.1) by
CT scans obtained about every six to eight weeks. Clinical
evaluation and assessments were performed per protocol.Genomic profiling
Next-generation sequencing was performed by using the
Clinical Laboratory Improvement Amendments (CLIA)-ap-
proved FoundationOne™ platform (Foundation Medicine,
Cambridge, MA, USA). FoundationOne™ is a targeted
assay utilizing next generation sequencing in routine can-
cer specimens. The assay simultaneously sequences the
entire coding sequence of 236 cancer-related genes (3,769
exons) plus 47 introns of 19 genes frequently rearranged
in cancer to a minimum coverage depth of 250X. The
assay detects all class of genomic alterations (including
base substitutions, insertions and deletions, copy numberalterations and rearrangements) using routine FFPE tissue
samples that may be as small as 0.6 mm3.
Results and discussion
Case history
A 55 year old female presented to the clinical center for tar-
geted therapy to discuss treatment options for a progressive
metastatic spindle cell neoplasm. Disease at presentation
included a left chest wall mass measuring more than 6 cm
in greatest dimension. Extent of disease evaluation also
revealed a lytic lesion in the left seventh rib and a second
smaller mass centered in the pleura.
Pathologic examination of formalin fixed paraffin em-
bedded (FFPE) biopsied tissue from the presumed pri-
mary tumor site revealed a spindle cell proliferation,
which was diagnosed to be a malignant spindle cell neo-
plasm, favor sarcoma, which is akin to a diagnosis of ex-
clusion. The diagnosis of a malignant solitary fibrous
tumor was also entertained, but the features were not
typical for such a diagnosis (Figure 1 A,B upper left and
right panels with 100× and 400× magnification, respect-
ively). Immunohistochemical stains for S-100 and CD34
were positive (Figure 1 C,D lower left and right panels,
respectively). Notably, mitoses were counted at 6/10 per
high powered field (HPF), and no necrosis was identified.
Using FNCLCC guidelines for the histopathologic grading
of soft tissue sarcomas as a reference, this difficult to
characterize neoplasm would be intermediate grade [1].
The patient was initially treated with doxorubicin
(Adriamycin®) 75 mg/m2 and ifosfamide (Ifex®) 10 g/m2.
She progressed during two cycles of this treatment, and
was then started on gemcitabine (Gemzar®) 900 mg/m2
and docetaxel (Taxotere®) 100 mg/m2. The patient then
progressed after two cycles of her second regimen.
The patient was then enrolled in a phase I clinical trial
(ClinicalTrials.gov Identifier: NCT01187199) of bevaci-
zumab and temsirolimus in combination with sorafenib
for the treatment of advanced cancer [2]. The patient
was treated with bevacizumab 10 mg/kg intravenously
(IV) every 21 days, temsirolimus 20 mg IV on Day 1, 8
and 15, and sorafenib 200 mg orally twice daily. After of
two cycles of therapy, the patient had a 25% reduction
in greatest unidimensional tumor measurment per
RECIST 1.1 (Figure 2 A,B), which is stable disease (SD),
and also just below the criteria for a partial response
(PR). Pain secondary to the chest wall mass decreased
and dyspnea, likely secondary to the resolving pleural
effusion, lessened. She tolerated therapy well, except for
experiencing grade 3 hypertension related to bevacizu-
mab that required anti-hypertensive therapy. She also
had grade 2–3 hand-foot-syndrome related to sorafenib,
leading to a dose reduction to 200 mg once daily. The
patient continued on therapy for seven months since
the initiation of therapy.
Figure 1 Histopathologic examination of formalin fixed paraffin embedded (FFPE) biopsied tissue from the presumed primary tumor
site. (A) Low power (100x). Cellular tumor composed of spindled cells. (B) High power (400x). Short atypical spindle cells with few mitotic figures.
Immunohistochemical studies reveal the tumor to be reactive for (C) S-100 protein and (D) CD34.
Subbiah et al. Journal of Hematology & Oncology 2014, 7:8 Page 3 of 6
http://www.jhoonline.org/content/7/1/8Contemporaneously with the entrance of patient into
the clinical trial, FFPE tumor cell-predominant tissue from
the biopsy was submitted to a commercial CLIA-certified,
CAP-accredited laboratory for genomic profiling based on
next generation sequencing (NGS) based.A
Figure 2 Imaging studies pre and post- treatment. A: Pre-treatment CT
left sided pleural effusion. B. Post-treatment CT scan of the Chest shows aAt the time of this report, the patient’s overall re-
sponse was stable disease for eleven cycles. She had the
following ongoing toxicities that were felt to be at least
possibly related to the study drug: grade 1 altered taste,
grade 2 proteinuria, grade 1 hand-foot syndrome, gradeB
scan of the Chest shows left chest wall tumor invading the ribs and
decrease in size of the tumor and decrease in pleural effusion.
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did not experience a dose limiting toxicity from the
combination therapy. Unfortunately, the patient developed
an acute myocardial infarction, hypotension, clinically de-
teriorated and died because of this co-morbidity.
Genomic profiling
3769 exons of 236 cancer-related genes and 47 introns
from 19 genes frequently rearranged in cancer were se-
quenced to a depth of coverage of 835×. A tandem du-
plication predicted to generate a KIAA1549-BRAF fusion
gene (Figure 3), was identified as well as a homozygous
deletion of PTEN. Other genomic alterations identified in
this tumor were frameshift insertion/deletions in CDKN2A
A68fs*51, SUFU E283fs*3, andMAP3K1 N325fs*3.
Discussion
KIAA1549-BRAF is a recurrent oncogenic driver in spor-
adic pilocytic astrocytoma, but is described here in a spin-
dle cell neoplasm for the first time [3]. To our knowledge,
moreover, this case is the first report any tumor expressing
this fusion to be successfully treated by targeted therapy.
The patient initially received two lines of standard chemo-
therapy for soft tissue sarcoma, and did not respond. For
this patient, the administered combination of sorafenib,
temsirolimus, and bevacizumab provided durable disease
control and symptomatic benefit. Likely, the magnitude
and rapidity of this response was due to treatment thatFigure 3 KIAA1549-BRAF fusion protein. Of the two components of the
kinase that is activated by binding of RAS-GTP. The function of KIAA1549 re
of BRAF, although several other configurations of these fused genes have b
retained but the N-terminal conserved region 1 (CR1) and conserved regio
inhibitory allosteric interaction is disrupted by the binding of RAS-GTP to C
activity of this fusion.precisely and fortuitously targeted the genomic alterations
present in this tumor.
A possible pathologic diagnosis for this tumor could
be that of a malignant peripheral nerve sheath tumor
(MPNST) due to the positive S100 immunohistochemical
stain and histologic phenotype of spindle cells, although
that diagnosis was not made here. Interestingly, the known
activating V600E BRAF mutation is observed in a non-
syndromic and sporadic subset of MPNST cases [4]. The
identification of a BRAF fusion in this spindle cell tumor
is consistent with molecular and phenotypic correlation of
an activated BRAF in some MPNST cases.
Of the two components of the KIAA1549-BRAF fusion
protein, BRAF is a cytosolic serine/threonine kinase that
is activated by binding of RAS-GTP. The function of
KIAA1549 remains unknown. This fusion joins intron 15
of KIAA1549 and intron 8 of BRAF, although several other
configurations of these fused genes have been observed
[5]. The kinase domain and ATP binding pocket of BRAF
are retained but the N-terminal conserved region 1 (CR1)
and conserved region 2 (CR2) are lost. CR1 auto-inhibits
the kinase domain, but this inhibitory allosteric interaction
is disrupted by the binding of RAS-GTP to CR1. Thus,
loss of the CR1 domain suggests a dysregulation of the
kinase activity of this fusion.
Sorafenib is a small molecule inhibitor of WT BRAF
and other kinases including VEGFR 1/2/3, PDGFRB, and
RAF family, that has an IC50 for WT BRAF at 25 nmKIAA1549-BRAF fusion protein, BRAF is a cytosolic serine/threonine
mains unknown. This fusion merges intron 15 of KIAA1549 and intron 8
een observed. The kinase domain and ATP binding pocket of BRAF are
n 2 (CR2) are lost. CR1 auto-inhibits the kinase domain, but this
R1. Thus, loss of the CR1 domain suggests a dysregulation of the kinase
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binding cleft to indirectly compete with ATP. The struc-
ture of the fusion protein readily suggests that sorafenib
may also inhibit activity of KIAA1549-BRAF as the BRAF
kinase domain is completely conserved. Interestingly suc-
cessful targeting by sorafenib of BRAF-fusion bearing cells
specifically the AGK-BRAF fusion that contains the first 33
amino acids of AGK and the C-terminal portion of BRAF
starting from position 328 of BRAF with loss of the CR1
domain (not KIAA1549-BRAF) has been recently reported
[7]. In the experiments carried out the patient-derived
AGK-BRAF expressing melanoma cell line demonstrated
an increased sensitivity to sorafenib [7]. Remarkably, soraf-
enib was also active against RAF fusion proteins reported
in prostate cancer [8].
Notably, pediatric astrocytoma patients expressing this
fusion progressed on sorafenib monotherapy in a small
phase II trial [9]. This observation suggests that sole
inhibition of the BRAF fusion is insufficient for tumor
response. An analogy can be made to non-melanoma
solid tumors expressing the activating V600E mutant
BRAF, where vemurafenib treatment is sometimes inef-
fective, ie as in the colon [10]. In such instances of resist-
ance aberrant activation of the P13K/PTEN/mTOR
pathway has been implicated [10-12]. This leads to the
premise that combined BRAF and mTOR pathway inhib-
ition may overcome the innate and/or acquired resistance
[13-16] to BRAF-target monotherapy, as has been dem-
onstrated in other systems [17]. Thus, the combination
therapy administered in this patient seemingly targeted
the existing genomic alterations. Interestingly, in murine
models of pilocytic astrocytoma, the KIAA1549-BRAF fu-
sion hyperactivates the mTOR pathway [18], as does loss
of PTEN [18]. In this context, the success of this combin-
ation therapy suggests both inhibition of the BRAF fusion
protein by sorafenib and of the downstream mTOR
pathway by temsirolimus synergizes, although the spe-
cific mechanism of tumor regression awaits further
investigation. Bevacizumab was also administered, but
the contribution of this therapy to the patient response
is difficult to ascertain. As has been theorized for other
tumor types, it is possible that bevacizumab enhanced
delivery of the other therapeutics by normalizing the
tumoral vasculature [19].
What are the implications of this case for treating
tumors that express the KIAA1549-BRAF fusion such
as pediatric pilocytic astrocytomas?
As patients with such tumors on sorafenib monother-
apy progressed rapidly in a very small Phase II study [9],
sorafenib combination therapy combined with mTOR
inhibitors is an alternative avenue. While this is suggest-
ive, additional in vitro and in vivo studies well outside
the scope of this report are required. Sorafenib is indeed
not a specific inhibitor of BRAF and as such the effectsmay not be mediated by targeting KIAA1549-BRAF in
this tumor.
Specifically, genomic profiling based on clinical-grade
NGS could identify whether PTEN loss or other GAs acti-
vating the mTOR pathway are present alongside the BRAF
fusion in a pilocytic astrocytoma of patient, thus sug-
gesting a potential responsiveness to combined sorafenib/
mTOR targeted therapy. As a possible therapeutic alter-
native, a recent in vitro study suggested that second
generation BRAF inhibitors may be capable of effect-
ively inhibiting this fusion protein [20].
Conclusions
A prospective clinical trial with prospective diagnostic
genomic profiling will best answer whether tumors driven
by KIAA1549-BRAF fusions typically coincide with alter-
ations in the mTOR pathway, and whether such patients
can be effectively treated with targeted therapy on that
basis. However, this case already indicates such treatment
possibilities exist for patients possessing KIAA1549-BRAF
fusions, whether in pediatric astrocytomas or difficult to
characterize sarcoma like lesions. In general, genomic pro-
filing based on NGS may be of great relevance in the man-
agement of patient with solid tumors that defy pathologic
definition, as this case demonstrates that such diagnostics
can reveal unexpected but effective avenues of targeted
treatment.
Findings
 KIAA1549-BRAF fusion, a recurrent oncogenic
driver in sporadic pilocytic astrocytoma, is described
here in a spindle cell neoplasm for the first time.
 This case is the first report any tumor expressing
KIAA1549-BRAF fusion with PTEN loss to be
successfully treated by targeted therapy.
 Genomic profiling based on Next-generation
sequencing (NGS) may be of great relevance in the
management of patient with solid tumors that defy
pathologic definition, as this case demonstrates that
such diagnostics can reveal unexpected but effective
avenues of targeted treatment.
Competing interests
KW, SMA, VAM, PJS, GAP, and JSR are all employees of and own stock in
Foundation Medicine.
Authors’ contributions
All authors contributed to writing the manuscript. VS, VAM and SMA
conceived the manuscript. VS and DA provided clinical expertise. SNW is the
primary investigator for the clinical trial and VS is the co-primary investigator
for the clinical trial. VS, SNW, KW, WW, VAM, JR, PJS, GAP and SMA analyzed
the data. WW, JR, SMA provided pathology expertise. VS and SMA wrote the
paper. VS and DA provided sarcoma expertise. VS and SMA provided cellular,
molecular and targeted therapy expertise. All authors read and approved the
final manuscript.
Subbiah et al. Journal of Hematology & Oncology 2014, 7:8 Page 6 of 6
http://www.jhoonline.org/content/7/1/8Acknowledgements
VS would like to thank the patient and family for their motivation in seeking
targeted therapy. VS and SNW would like to thank Melody Smart, the clinical
research coordinator for assistance in scheduling the patient visits. The
University of Texas MD Anderson Cancer Center is supported by Cancer
Center Support Grant no. CA 016672.
SW is supported by a K12 Paul Calabresi Clinical Oncology Research Career
Development Grant, K12 CA88084. VS has clinical trial research support from
Genentech/Roche, GSK and Northwest Biotherapeutics.
Author details
1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials
Program), Division of Cancer Medicine, The University of Texas MD Anderson
Cancer Center, 1515 Holcombe Blvd., FC8.3038, Box 0455, Houston, TX 77030,
USA. 2Foundation Medicine, Cambridge, Massachusetts, USA. 3Department of
Sarcoma Medical Oncology, Division of Cancer Medicine, The University of
Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030,
USA. 4Division of Pathology, The University of Texas MD Anderson Cancer
Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. 5Division of
Gynecologic Oncology and Reproductive Medicine, The University of Texas
MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
6Department of Pathology, Albany Medical Center, Albany, NY 12222, USA.
Received: 4 October 2013 Accepted: 31 December 2013
Published: 14 January 2014References
1. Trojani MCG, Coindre JM, Rouesse J, Bui NB, de Mascarel A, Goussot JF,
David M, Bonichon F, Lagarde C: Soft-tissue sarcomas of adults; study of
pathological prognostic variables and definition of a histopathological
grading system. Int J Cancer 1984, 33:37–42.
2. Westin S, Smart ML, Pal N, Urbauer DL, Janku F, Wheler JJ, Piha-Paul SA,
Naing A, Simberidou AMT, Fu S, Falchook GS, Hong DS, Zinner R, Subbiah V,
Culotta KS, Lu KH, Coleman RL, Kurzrock R: Phase I trial of sorafenib,
bevacizumab, and temsirolimus in advanced solid tumors. J Clin Oncol
2013. ASCO Annual Meeting Abstracts 2013, suppl; abstr 2611. 31(15):2611.
3. Dimitriadis E, Alexiou GA, Tsotsou P, Simeonidi E, Stefanaki K, Patereli A,
Prodromou N, Pandis N: BRAF alterations in pediatric low grade gliomas
and mixed neuronal-glial tumors. J Neurooncol 2013, 113(3):353–358.
4. Serrano C, Simonetti S, Hernandez-Losa J, Valverde C, Carrato C, Bague S,
Orellana R, Somoza R, Moline T, Carles J, et al: BRAF V600E and KRAS G12S
mutations in peripheral nerve sheath tumours. Histopathology 2013,
62(3):499–504.
5. Gronych J, Korshunov A, Bageritz J, Milde T, Jugold M, Hambardzumyan D,
Remke M, Hartmann C, Witt H, Jones DTW, et al: An activated mutant
BRAF kinase domain is sufficient to induce pilocytic astrocytoma in
mice. J Clin Invest 2011, 121(4):1344–1348.
6. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF,
Altman RB, Klein TE: Pharmacogenomics knowledge for personalized
medicine. Clin Pharmacol Ther 2012, 92(4):414–417.
7. Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M,
Rocchi S, Bahadoran P, McCalmont TH, et al: Recurrent BRAF kinase fusions
in melanocytic tumors offer an opportunity for targeted therapy.
Pigment Cell Melanoma Res 2013, 26(6):845–851.
8. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K,
Shankar S, Han B, Cao Q, Cao X, Suleman K, et al: Rearrangements of the
RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Nat Med 2010, 16(7):793–798.
9. Karajannis M, Fisher MJ, Milla SS, Cohen KJ, Legault G, Wisoff JH, Harter DH,
Hartnett E, Merkelson A, Bloom MC, Dhall G, Jones D, Korshunov A, Pfister S,
Eberhart CG, Zagzag D, Allen JC: Ot-02. phase ii study of sorafenib in
children with recurrent/progressive low-grade astrocytomas. Neuro Oncol
2012, 14(suppl 6):vi101–vi105.
10. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, Gopal YN,
Jiang ZQ, Wistuba II, Tang XM, et al: Resistance to BRAF inhibition in
BRAF-mutant colon cancer can be overcome with PI3K inhibition or
demethylating agents. Clin Cancer Res 2013, 19(3):657–667.
11. Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC,
Blackman SC, Kurzrock R: BRAF mutant gastrointestinal stromal tumor:
first report of regression with BRAF inhibitor dabrafenib (GSK2118436)and whole exomic sequencing for analysis of acquired resistance.
Oncotarget 2013, 4(2):310–315.
12. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM,
Lopes JM, Sobrinho-Simoes M, Soares P: mTOR pathway overactivation in
BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 2012,
97(7):E1139–E1149.
13. Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV,
Vecchione L, de Vriendt V, Weinstein BJ, et al: Concomitant BRAF and PI3K/
mTOR Blockade Is Required for Effective Treatment of BRAFV600E
Colorectal Cancer. Clin Cancer Res 2013, 19(10):2688–2698.
14. Wang J, Kobayashi T, Floc'h N, Kinkade CW, Aytes A, Dankort D, Lefebvre C,
Mitrofanova A, Cardiff RD, McMahon M, et al: B-Raf activation cooperates
with PTEN loss to drive c-Myc expression in advanced prostate cancer.
Cancer Res 2012, 72(18):4765–4776.
15. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN,
Dickerson SH, Laquerre SG, Liu L, Gilmer TM: Combinations of BRAF, MEK,
and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF
inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Mol Cancer Ther 2012, 11(4):909–920.
16. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B,
Glaspy JA, Comin-Anduix B, et al: Reversing melanoma cross-resistance to
BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PloS One 2011, 6(12):e28973.
17. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R,
Anderson P, Kurzrock R: Targeted morphoproteomic profiling of Ewing's
sarcoma treated with insulin-like growth factor 1 receptor (IGF1R)
inhibitors: response/resistance signatures. PloS One 2011, 6(4):e18424.
18. Kaul A, Chen YH, Emnett RJ, Dahiya S, Gutmann DH: Pediatric
glioma-associated KIAA1549:BRAF expression regulates neuroglial cell
growth in a cell type-specific and mTOR-dependent manner. Genes Dev
2012, 26(23):2561–2566.
19. Jain RK: Normalization of tumor vasculature: an emerging concept in
antiangiogenic therapy. Science 2005, 307(5706):58–62.
20. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N,
Kellet M, Storm PB, Resnick AC: Paradoxical activation and RAF inhibitor
resistance of BRAF protein kinase fusions characterizing pediatric
astrocytomas. Proc Natl Acad Sci 2013, 110(15):5957–5962.
doi:10.1186/1756-8722-7-8
Cite this article as: Subbiah et al.: Targeted therapy by combined
inhibition of the RAF and mTOR kinases in malignant spindle cell
neoplasm harboring the KIAA1549-BRAF fusion protein. Journal of
Hematology & Oncology 2014 7:8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
